Quince Therapeutics Amends Credit Facility Agreement

Quince Therapeutics ( (QNCX) ) has provided an update.

On September 25, 2025, Quince Therapeutics amended its unsecured credit facility agreement with the European Investment Bank, initially established in 2020. The amendment reduces the company’s required minimum cash balance from EUR 14,650,000 to EUR 5,000,000 for the period from January 1, 2026, to March 31, 2026, and adjusts the interest rate terms for Tranche A and Tranche B, impacting the company’s financial flexibility and operational strategy.

The most recent analyst rating on (QNCX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Quince Therapeutics stock, see the QNCX Stock Forecast page.

Spark’s Take on QNCX Stock

According to Spark, TipRanks’ AI Analyst, QNCX is a Underperform.

Quince Therapeutics faces substantial financial challenges with no revenue, consistent losses, and negative cash flows, severely impacting its financial performance score. Technical analysis provides mixed signals, with some indicators suggesting potential momentum but overall bearish trends. Valuation remains unattractive due to the negative P/E ratio and lack of dividend yield. The absence of earnings call and corporate events data limits further insights.

To see Spark’s full report on QNCX stock, click here.

More about Quince Therapeutics

Quince Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of therapeutic products. The company collaborates with various entities, including EryDel Italy, Inc., EryDel US, Inc., EryDel USA, Inc., and EryDel S.p.A., and engages in financial agreements with institutions like the European Investment Bank.

Average Trading Volume: 200,990

Technical Sentiment Signal: Buy

Current Market Cap: $87.02M

Learn more about QNCX stock on TipRanks’ Stock Analysis page.